Express News | Incannex Healthcare Inc: Intends to Submit Nda for Ihl-42X Fixed Dose Combination Drug to FDA Using 505(B)2 Pathway
Moomoo 24/7Apr 16 08:10 ET
Incannex Healthcare Inc. Quarterly Update, Q1 2024
MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), ('Incannex' or the 'Company'), is pleased to prov
GlobeNewswireApr 16 08:00 ET
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
BenzingaMar 29 12:43 ET
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
BenzingaMar 20 14:49 ET
Incannex Healthcare Appoints New CFO and Secretary
InvestingMar 5 07:12 ET
Incannex Healthcare Tapped Treasurer and Controller Joseph Swan to Additional Role of CFO, Effective February 29 After Madhukar Bhalla Decided to Retire
Madhukar Bhalla, Chief Financial Officer and Secretary of Incannex Healthcare Inc. (the "Company"), recently notified the Company of his decision to resign from his positions effective as of February
BenzingaMar 5 06:21 ET
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized AnxietyPsilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits f
BenzingaMar 4 13:48 ET
Ampio Pharmaceuticals, Ironwood, Incannex Among Healthcare Movers
Seeking AlphaFeb 29 10:00 ET
KLIC, IRWD and GRFS Among Pre-market Losers
Seeking AlphaFeb 29 08:32 ET
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.) With variable symptoms, the condition typically involves a per
BenzingaFeb 28 14:33 ET
What's Going On With Incannex Stock?
Incannex Healthcare Inc. (NASDAQ:IXHL) shares are trading higher Wednesday after the company announced its Psi-GAD1 trial met its primary endpoint.The Details:Incannex said that its Phase 2 Psi-GAD1 c
BenzingaFeb 28 11:58 ET
Express News | Incannex Healthcare Shares Halted On Circuit Breaker To The Downside, Stock Now Up 72.8%
Moomoo 24/7Feb 28 09:40 ET
Express News | Incannex Shares Are Trading Higher After the Company Announced Its Psi-GAD1 Trial Met Its Primary Endpoint
Moomoo 24/7Feb 28 09:27 ET
Incannex Healthcare Shares Soar Premarket on Psilocybin Study
By Colin Kellaher Incannex Healthcare shares surged more than 80% in premarket trading Wednesday after the biotechnology company reported positive top-line results from a Phase 2 study of psilocybin
WSJFeb 28 08:59 ET
Incannex Stock Surges as Anxiety Disorder Study Meets Primary Goal
Seeking AlphaFeb 28 08:38 ET
Express News | Market-Moving News for February 28th
Moomoo 24/7Feb 28 08:33 ET
Incannex Announces Positive Topline Results From Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
Highlights: PsiGAD1 trial achieves primary endpoint; PsiGAD psilocybin-assisted therapy demonstrated a statistically significant HAM-A reduction of 12.8 points from baseline, representing a 9.2-point improvement over
GlobeNewswireFeb 28 07:30 ET
SNCR, JANX and GBNH Among Mid-day Movers
Seeking AlphaFeb 21 12:27 ET
Express News | Incannex Healthcare Shares Resume Trade
Moomoo 24/7Feb 21 12:09 ET
Express News | Incannex Healthcare Shares Halted On Circuit Breaker To The Upside, Stock Now Up 62.3%
Moomoo 24/7Feb 21 12:04 ET
No Data
No Data